论文部分内容阅读
NCCN guideline for AML Number of HSCT cases in PUIH Dose allogeneic hematopoietic stem cell transplantation benefit all patients with AMLin CR1 ? Who and wich type? HSCT for patients aged <60 years old HSCT for unfavorable risk AML in CR1 Does patients with intermediate-or high risk AML in CR1 benefit from allogeneic HSCT? Which type of allogeneic HSCT will be chosen?